EUPRAXIA PHARMACEUTICALS

COMPANY PROFILE

Eupraxia is a clinical-stage biotechnology company focused on the development of innovative, locally delivered extended-release products in conjunction with currently approved drugs.

Each of **Eupraxia**'s product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

- the **Right Dose** of the drug
- in the **Right Place** for the
- **Right amount of time**

Intellectual Property Platform

✓ Initial patents filed in all major markets with coverage into 2034

MARKET DATA

Exchange: Ticker	**TSX: EPRX**
Recent Share Price (November 14, 2023)	$6.72
Common Shares Outstanding (Sep 30, 2023)	27.2 million
Fully Diluted Common Shares (Sep 30, 2023)	42.7 million
Market Capitalization	$195
52-week Range	$1.04 - $9.10
Board & Mgmt. (As of August 11, 2023)	~11% (Basic)/ ~18% (FD)
Cash on Hand (September 30, 2023)	$33.2 million

cg/ Canaccord Genuity | RAYMOND JAMES | RESEARCH CAPITAL CORPORATION

THE EUPRAXIA ADVANTAGE

1. **Significant Near-Term, Value Driving Catalysts**
   Product near end of clinical trials & moving closer to potential commercialization
2. **Robust Pipeline**
   Of clinical and non-clinical product candidates
3. **NASDAQ Listing**
   Intention for near-term listing pending market conditions

SCIENCE

Osteoarthritis (OA) is the leading cause of disability in older adults.

Eupraxia's lead candidate, EP-104 has two primary targets identified as knee osteoarthritis and eosinphillic esophagitis (EoE). EP-104 **is designed to improve symptoms and quality of life in all patient populations**.

EP-104 has the potential to be differentiated by dosing, concentrations, delivery vehicle and the route of administration.



Traditional extended-release profile

Eupraxia targeted release profile

✓ Reduced side effects
✓ Longer lasting

LEAD CANDIDATE – EP-104IAR / EP-104GI



1 Includes other inflammatory joint conditions, benign strictures of the esophagus, epidural delivery 2. Currently on hold

EP-104IAR – Osteoarthritis (Knee Pain)

- End of Phase 2 meeting with FDA – **Q1 2024**
- Start of Phase 3 study – **H1 2023**
  - Conduct similar trial to build safety database of 500 patients
  - Est. Phase 3 trial length of 24-30 months
  - Focus on U.S. market – BD opportunity outside of U.S

EP-104GI – Eosinophilic

- ✓ Initiate second cohort in Phase 1b/2a clinical trial - **Q4 2023**
- EoE interim data readout – **Q4 2023**
- Proof of concept data - **Q1 2024**
- Pre-IND meeting with FDA - **Q2 2024**
- Sites in the Netherlands, Canada and Australia

LEADERSHIP

JAMES HELLIWELL, MD
CEO & Co-Founder, Director

- Prior to founding Eupraxia, he held a clinical practice at a quaternary academic cardiac center in St. Paul's Hospital, Vancouver. He also served as Clinical Assistant Professor at the University of British Columbia in the Department of Anesthesiology, Pharmacology and Therapeutics
- Medical degree from the University of British Columbia, and Fellowship Certification in Cardiac Anesthesiology and transplantation, and board certification in Perioperative Echocardiography

AMANDA MALONE
CSO & Co-Founder

- 15+ years experience in the development of drug delivery systems. Prior to joining Eupraxia, Dr. Malone was the VP and COO of a drug-delivery focused biotech, Auritec Pharmaceuticals
- PhD in Mechanical and Bioengineering from Stanford University. Bachelor of Science in Engineering from Harvey Mudd College